Magenta Therapeutics Highlights Recent Pipeline Progress and Milestone Expectations for 2022

Fulcrum Therapeutics® Announces Upcoming Milestones to Support Its Mission of Treating the Root Cause of Rare Genetic Diseases

Allena Pharmaceuticals Provides Clinical and Corporate Update

Fulcrum Therapeutics® Appoints Esther Rajavelu as Chief Financial Officer

Ambys Completes $47 Million Series A Extension to Advance Liver Cell Therapy Platform

Asher Bio Showcases Versatility and Broad Applicability of Cis-Targeting Technology for Precision Immunotherapies at Antibody Engineering Conferences

Magenta Therapeutics Highlights Presentations Of Data Related To Stem Cell Mobilization And Targeted Conditioning At The 2021 American Society Of Hematology (ASH) Annual Meeting

Rheos Medicines Presents New Data Supporting MALT1 Inhibition as Novel Strategy for Precision Medicine-Based Approach to Treating Chronic Graft-Versus-Host Disease

Nurix Therapeutics Announces Regulatory Clearance to Initiate Phase 1 Clinical Trial of NX-5948 and Presents New Preclinical Data at the American Society of Hematology Annual Meeting

Decibel Therapeutics Announces Appointments of Alison Finger, MBA and Saraswathy Nochur, Ph.D. to its Board of Directors; Christine Poon Steps Down from Board

Ambys Medicines Announces Appointment of Founder Markus Grompe, M.D., as Chief Scientific Officer

Fulcrum Therapeutics® Announces Additional HBG mRNA Induction from Higher Dose Cohorts in Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease and New Preclinical Mechanism Data

Goldfinch Bio Strengthens Leadership Team with Appointment of Jeff W. Jacobs, Ph.D. as Chief Scientific Officer

Decibel Therapeutics Announces Extension of Research Term under Strategic Collaboration with Regeneron to Discover and Develop Gene Therapies for Hearing Loss

Voyager Therapeutics Announces Positive Preclinical Data From New Vectorized Anti-HER2 Antibody Program At The 26th Society For Neuro-Oncology Annual Meeting

Fulcrum Therapeutics® Appoints Sonja L. Banks to its Board of Directors

Cedilla Therapeutics Expands Leadership Team with Key Appointments Across R&D And Finance

Nurix Therapeutics Announces IND clearance for DeTIL-0255, a drug-enhanced autologous T cell therapy for the potential treatment of a variety of solid tumors

Nurix Therapeutics Presents Beneficial Effects of CBL-B Inhibition on Human Tumor Infiltrating Lymphocytes at SITC Conference

Asher Bio Announces New Preclinical Data Demonstrating Best-in-Class Potential of AB248, its Lead Cis-targeted IL-2 Immunotherapy

Revolution Medicines Reports Third Quarter Financial Results and Update on Corporate Progressre

Decibel Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update

Allena Pharmaceuticals Reports Third Quarter 2021 Financial Results and Recent Corporate Progress

Tango Therapeutics Reports Third Quarter 2021 Financial Results And Provides Business Highlightst

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results

Sesen Bio Reports Third Quarter 2021 Financial Results and Business Update

Goldfinch Bio Showcases Biology, Genetic and Clinical Programs at ASN Kidney Week Demonstrating Leadership in Precision Medicines for Kidney Diseases

Fulcrum Therapeutics® Reports Recent Business Highlights and Third Quarter 2021 Financial Results

Jounce Therapeutics Reports Third Quarter 2021 Financial Results

Allena Pharmaceuticals Receives Fast Track Designation from FDA for the Development of ALLN-346 for Chronic Treatment of Hyperuricemia in Patients With Gout and Advanced Chronic Kidney Disease

Voyager Therapeutics Reports Third Quarter 2021 Financial And Operating Results

Tango Therapeutics Announces Appointment Of Dr. Marc Rudoltz As Chief Medical Officer And Doug Barry As General Counsel

Rheos Medicines Presents Data Demonstrating Potential of MALT1 Inhibition as Novel Approach for the Treatment of Autoimmune and Inflammatory Diseases

Nurix Therapeutics Announces Initial Data from the First Phase 1a Dose Escalation Trial of NX-2127 in Patients with Relapsed or Refractory B Cell Malignancies

Rheos Medicines Forms Research Collaboration with CRYOSTEM to Evaluate MALT1 Targeted Therapeutics for Graft-versus-Host-Disease

Flare Therapeutics Appoints Daphne Karydas As COO And CFO, And Michaela Bowden, PhD, As SVP Of Biology And Translation

Cedilla Therapeutics Completes $82.6M Series B Financingc

Cedilla Therapeutics Unveils Lead Programs for the Conditional Inhibition of TEAD and CDK2, Two High Value and Historically Undruggable Cancer Drivers

Voyager Therapeutics Presents Positive Preclinical Data Supporting CNS-Directed GBA1 Gene Therapy At Virtual Congress Of The European Society Of Gene And Cell Therapy

Goldfinch Bio Announces Upcoming Presentations at American Society of Human Genetics (ASHG) 2021 Meeting and American Society of Nephrology’s (ASN) Kidney Week 2021go

Rheos Medicines to Present Data at ACR 2021 for MALT1 Inhibitors in Autoimmune and Inflammatory Disease and Announces RHX-317 as First Development Candidate

Ambys Medicines announces John Choi is joining as VP of Regulatory Affairs as it initiates IND activities for its lead allogeneic liver cell transplantation program

Sesen Bio Expands CMC and Clinical Teams

Pliant Therapeutics to Participate in Piper Sandler Lung Day

Jounce Therapeutics Progresses INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monotherapy and Pimivalimab (PD-1 Inhibitor) Combination Therapy in Patients with Advanced Solid Tumors

Voyager Therapeutics Announces License Option Agreement With Pfizer For Next-Generation TRACERᵀᴹ AAV Capsids To Enable Neurologic And Cardiovascular Gene Therapy Programs

MOMA Therapeutics Appoints Hans Bitter, Ph.D., as Senior Vice President and Head, Data Sciencem

Magenta Therapeutics Appoints Jeffrey Humphrey, M.D. As Chief Medical Officer

Casma Therapeutics Announces Publication in Science Advances Highlighting Novel Mechanism Related to TFEB Activation and Lysosomal Biology

Asher Bio to Present Preclinical Proof-of-Concept Data for AB248, a Highly Selective CD8-targeted IL-2 Therapy, at SITC 2021